Clinical considerations for the development of biosimilars in oncology - Wikidata - wikimedia - TriplyDB

Clinical considerations for the development of biosimilars in oncology

Clinical considerations for the development of biosimilars in oncology

http://www.wikidata.org/entity/Q28081768

about

Biosimilars: potential implications for clinicians A practical guide about biosimilar data for health care providers treating inflammatory diseases A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.Patient attitudes and understanding about biosimilars: an international cross-sectional survey The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects An introduction to biosimilar cancer therapeutics: definitions, rationale for development and regulatory requirements.Statistical Primer on Biosimilar Clinical Development.Characterization and non-clinical assessment of the proposed etanercept biosimilar GP2015 with originator etanercept (Enbrel(®)).Biosimilars and the extrapolation of indications for inflammatory conditions.Biosimilar biologic drugs: a new frontier in medical care.Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future.Biosimilars Have Arrived: Rituximab.Biosimilars: Review of current applications, obstacles, and their future in medicine

P2860

Q26744332-05FFE92B-7D21-4FD9-BA44-8B671BE929F9 Q36303459-DCD57203-8DCB-4500-9C5F-111888262853 Q36762864-8A79B964-B6CE-4C33-934E-D4074C202DFD Q36956527-0F88A76D-3788-4485-AA86-E749781D9839 Q37732903-5D21F1FE-A0EA-4422-9FC1-DBD06CDB4672 Q38686393-06689663-C8FB-4BBC-B4E1-364A2A121C8B Q38696351-F116086A-2282-45A4-8676-E62D8569DC4F Q38910179-1B179725-FEA5-4048-A43E-31BE542062FD Q38932150-EF167B1F-4C6D-4499-884E-635CACF866A0 Q39200937-36AD5F14-B644-4B21-982F-CEBBDD2E35C2 Q50001689-8053FD7A-7E2F-4637-BD7E-84A3FE1C63B7 Q52651099-5FA51112-D0B5-4005-B244-D71D64207966 Q55105693-10EB4F77-B747-444E-97BC-4F6CB90CEDC4 Q57169149-6C970C02-22A1-4B72-9FC7-DB82390496D9

P2860

Clinical considerations for the development of biosimilars in oncology

http://www.wikidata.org/entity/Q28081768

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

Clinical considerations for the development of biosimilars in oncology

@ast

Clinical considerations for the development of biosimilars in oncology

@en

Clinical considerations for the development of biosimilars in oncology

@nl

type

label

Clinical considerations for the development of biosimilars in oncology

@ast

Clinical considerations for the development of biosimilars in oncology

@en

Clinical considerations for the development of biosimilars in oncology

@nl

prefLabel

Clinical considerations for the development of biosimilars in oncology

@ast

Clinical considerations for the development of biosimilars in oncology

@en

Clinical considerations for the development of biosimilars in oncology

@nl

P1433

Q28081768-ACE9D1A6-D6D0-417B-9D4C-FEBB1F64C35E

P1476

Q28081768-FDEBA56C-E579-46B5-94B2-33EB62A603F9

P2093

Q28081768-44652441-6D00-42E5-8954-662EB7CD0E9F

Q28081768-4AEB1E63-6621-4F55-9F4B-D4D40F6C02F7

Q28081768-6316D40A-C21D-411E-AB50-C79A2CD548F4

Q28081768-D0A427DC-C6C2-4536-9AF0-4441F511699A

Q28081768-EE11720F-9600-499A-A73D-5C6579511F0F

P275

Q28081768-44515F5F-BEB2-43FA-907C-054EFA36D6AB

P2860

Q28081768-0C77A662-2096-474F-A718-A47D15281FB8

Q28081768-10475B5A-B4D6-4406-945E-AFF4BEC8716E

Q28081768-11E379C6-3236-4DFF-B887-70F9EF0C0659

Q28081768-1F4C4339-938D-41C0-937C-0E330251A1AF

Q28081768-55C4E47C-7DE8-46E7-94BF-4F019E11F5DB

Q28081768-5AA6D830-DC49-4DC1-BDFF-FC8569F0DCBE

Q28081768-640AA4F9-1C5F-4B9D-8059-4E528C8AFB79

Q28081768-7DA12974-00A2-4F56-A16A-764170D1790E

Q28081768-82282DE9-FB4A-4E12-8923-CB63178E4A3E

Q28081768-856326B2-D15C-4C7B-9F32-4631850B9602

P304

Q28081768-13687B4D-55BC-4BFD-8A78-799E5328E6A5

P31

Q28081768-FFC60517-9D23-4DC9-9956-63F434912F30

P3181

Q28081768-E850554C-D6F9-43AA-BFE5-54759B7CDE89

P356

Q28081768-A1E61313-D98C-47A4-8F1F-85F9214B2B58

P407

Q28081768-6510272C-53C9-4B32-A0D6-3A811C967F72

P433

Q28081768-55FE4F37-9129-427B-B865-78BECF3FCD4F

P478

Q28081768-136743F9-92BC-401F-8AB4-9C2BA38D3772

P50

Q28081768-ECC75B29-B31C-41A1-AE84-F506D2A8DE2B

P5008

Q28081768-EF4766B0-49E0-4ADF-81EF-36D977120592

P577

Q28081768-FFA93002-4C95-4374-B24F-FAEFCFA9B8CE

P5875

Q28081768-DD19B795-0A7C-4038-8AEF-2FD9C580A061

P698

Q28081768-3EF3D424-40B9-471E-AE31-A2A9291A7866

P921

Q28081768-0EB45587-20B2-4DE3-9B8F-F4A8A28B6F12

Q28081768-324D5E85-4D66-40C2-96E6-1BCD26D3255A

P932

Q28081768-DEE8295A-DB24-42EF-929A-ACAA15F5C3A3

P3181

P356

19420862.2015.1008346

P1433

Monoclonal Antibodies

P1476

Clinical considerations for the development of biosimilars in oncology

@en

P2093

Barry Gumbiner

http://www.w3.org/2001/XMLSchema#string

Dolca Thomas

http://www.w3.org/2001/XMLSchema#string

Ira Jacobs

http://www.w3.org/2001/XMLSchema#string

Judith MacDonald

http://www.w3.org/2001/XMLSchema#string

Mark A Socinski

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 3.0 Unported

P2860

Biosimilars: the science of extrapolation.

A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points

Projections of the cost of cancer care in the United States: 2010-2020.

Pharmacoeconomic considerations in the treatment of breast cancer.

The economic pressures for biosimilar drug use in cancer medicine

Statistical assessment of biosimilar products.

Pharmacovigilance and biosimilars: considerations, needs and challenges.

Clinical experience with Zarzio® in Europe: what have we learned?

Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars.

P304

286-293

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

704347

http://www.w3.org/2001/XMLSchema#string

P356

10.1080/19420862.2015.1008346

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Giuseppe Curigliano

P5008

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271535145

http://www.w3.org/2001/XMLSchema#string

P698

25621390

http://www.w3.org/2001/XMLSchema#string

P921

biomedical investigative technique

P932

4623533

http://www.w3.org/2001/XMLSchema#string